Net Margin - Ryvu Therapeutics SA (WSE:RVU) - Alpha Spread
R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 54.2 PLN -0.18% Market Closed
Market Cap: 1.3B PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Net Margin
Ryvu Therapeutics SA

-168.9%
Current
-1 040%
Average
0%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-168.9%
=
Net Income
-93.9m
/
Revenue
55.6m

Net Margin Across Competitors

Country PL
Market Cap 1.3B PLN
Net Margin
-169%
Country US
Market Cap 1.4T USD
Net Margin
6%
Country US
Market Cap 234.3B USD
Net Margin
15%
Country US
Market Cap 200B USD
Net Margin
19%
Country KR
Market Cap 70.5T KRW
Net Margin
24%
Country CH
Market Cap 40B CHF
Net Margin
9%
Country US
Market Cap 43.7B USD
Net Margin
9%
Country US
Market Cap 39.9B USD
Net Margin
22%
Country US
Market Cap 29.6B USD
Net Margin
21%
Country IE
Market Cap 24.5B USD
Net Margin
9%
Country US
Market Cap 21.5B USD
Net Margin
18%

Profitability Report

View the profitability report to see the full profitability analysis for Ryvu Therapeutics SA.

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-168.9%
=
Net Income
-93.9m
/
Revenue
55.6m
What is the Net Margin of Ryvu Therapeutics SA?

Based on Ryvu Therapeutics SA's most recent financial statements, the company has Net Margin of -168.9%.